222 related articles for article (PubMed ID: 29257006)
1. 68Ga-PSMA-HBED-CC PET/CT imaging in Black versus White South African patients with prostate carcinoma presenting with a low volume, androgen-dependent biochemical recurrence: a prospective study.
Lengana T; van de Wiele C; Lawal I; Maes A; Ebenhan T; Boshomane T; Zeevaart JR; Ankrah A; Mokgoro N; Vorster M; Sathekge M
Nucl Med Commun; 2018 Feb; 39(2):179-185. PubMed ID: 29257006
[TBL] [Abstract][Full Text] [Related]
2.
Sathekge M; Lengana T; Maes A; Vorster M; Zeevaart J; Lawal I; Ebenhan T; Van de Wiele C
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):226-234. PubMed ID: 29101444
[TBL] [Abstract][Full Text] [Related]
3. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
[TBL] [Abstract][Full Text] [Related]
4. A Multicenter Prospective Clinical Trial of
McCarthy M; Francis R; Tang C; Watts J; Campbell A
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):801-808. PubMed ID: 30890448
[TBL] [Abstract][Full Text] [Related]
5.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
6. Intrapatient Comparison of 111In-PSMA I&T SPECT/CT and Hybrid 68Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer.
Rauscher I; Maurer T; Souvatzoglou M; Beer AJ; Vag T; Wirtz M; Weirich G; Wester HJ; Gschwend JE; Schwaiger M; Schottelius M; Eiber M
Clin Nucl Med; 2016 Sep; 41(9):e397-402. PubMed ID: 27276206
[TBL] [Abstract][Full Text] [Related]
7. Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [
Berliner C; Tienken M; Frenzel T; Kobayashi Y; Helberg A; Kirchner U; Klutmann S; Beyersdorff D; Budäus L; Wester HJ; Mester J; Bannas P
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):670-677. PubMed ID: 27896369
[TBL] [Abstract][Full Text] [Related]
8. Prospective, Multisite, International Comparison of
Emmett L; Metser U; Bauman G; Hicks RJ; Weickhardt A; Davis ID; Punwani S; Pond G; Chua S; Ho B; Johnston E; Pouliot F; Scott AM
J Nucl Med; 2019 Jun; 60(6):794-800. PubMed ID: 30442757
[TBL] [Abstract][Full Text] [Related]
9. Combined Early and Late [
Hohberg M; Kobe C; Täger P; Hammes J; Schmidt M; Dietlein F; Wild M; Heidenreich A; Drzezga A; Dietlein M
Mol Imaging Biol; 2019 Jun; 21(3):558-566. PubMed ID: 30105521
[TBL] [Abstract][Full Text] [Related]
10. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
[TBL] [Abstract][Full Text] [Related]
11. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
[TBL] [Abstract][Full Text] [Related]
12. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.
Rauscher I; Maurer T; Beer AJ; Graner FP; Haller B; Weirich G; Doherty A; Gschwend JE; Schwaiger M; Eiber M
J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524
[TBL] [Abstract][Full Text] [Related]
13. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of
Hofman MS; Eu P; Jackson P; Hong E; Binns D; Iravani A; Murphy D; Mitchell C; Siva S; Hicks RJ; Young JD; Blower PJ; Mullen GE
J Nucl Med; 2018 Apr; 59(4):625-631. PubMed ID: 28986512
[No Abstract] [Full Text] [Related]
14. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
15. Integrated
Lütje S; Cohnen J; Gomez B; Grüneisen J; Sawicki L; Rübben H; Bockisch A; Umutlu L; Pöppel TD; Wetter A
Nuklearmedizin; 2017 Jun; 56(3):73-81. PubMed ID: 28401244
[TBL] [Abstract][Full Text] [Related]
16. (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.
Sachpekidis C; Eder M; Kopka K; Mier W; Hadaschik BA; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1288-99. PubMed ID: 26753602
[TBL] [Abstract][Full Text] [Related]
17. PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [68Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancer.
Verburg FA; Pfister D; Drude NI; Mottaghy FM; Behrendt FF
Nuklearmedizin; 2017; 56(6):225-232. PubMed ID: 29044297
[TBL] [Abstract][Full Text] [Related]
18. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.
Dietlein M; Kobe C; Kuhnert G; Stockter S; Fischer T; Schomäcker K; Schmidt M; Dietlein F; Zlatopolskiy BD; Krapf P; Richarz R; Neubauer S; Drzezga A; Neumaier B
Mol Imaging Biol; 2015 Aug; 17(4):575-84. PubMed ID: 26013479
[TBL] [Abstract][Full Text] [Related]
19.
Schmidkonz C; Cordes M; Schmidt D; Bäuerle T; Goetz TI; Beck M; Prante O; Cavallaro A; Uder M; Wullich B; Goebell P; Kuwert T; Ritt P
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1862-1872. PubMed ID: 29725716
[TBL] [Abstract][Full Text] [Related]
20. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
Sanli Y; Kuyumcu S; Sanli O; Buyukkaya F; İribaş A; Alcin G; Darendeliler E; Ozluk Y; Yildiz SO; Turkmen C
Ann Nucl Med; 2017 Nov; 31(9):709-717. PubMed ID: 28900854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
